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Abstract
 
CD22, a negative regulator of B cell antigen receptor signaling, binds glycoconjugates termi-
nating in 
 
 
 
2, 6 sialic acid. The physiological ligand(s) for CD22 remain unknown. We asked
whether the sialic acid binding domains are necessary for CD22 to function as a negative regu-
lator. We generated two mutants that lack sialic acid binding activity and expressed them in a
novel CD22
 
 
 
/
 
 
 
 murine B cell line. Anti-IgM activated B cells expressing either CD22 mutant
had greater Ca
 
2
 
 
 
 responses than cells expressing wild-type CD22. Each variant also had re-
duced CD22 tyrosine phosphorylation and Src homology 2 domain–containing protein ty-
rosine phosphatase-1 association. These data suggest that the 
 
 
 
2, 6 sialic acid ligand binding ac-
tivity of CD22 is critical for its negative regulatory functions.
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Introduction
 
CD22 is a type I transmembrane glycoprotein expressed on
mature B cells that specifically recognizes 
 
 
 
2, 6 sialic acid.
It has seven Ig-like extracellular domains and three cyto-
plasmic immunoreceptor tyrosine-based inhibitory motifs
(ITIMs). CD22 is a member of the rapidly growing family
of Siglec (sialic acid–binding Ig domain–containing lectin)
proteins (for a review, see reference 1). Siglecs, such as
sialoadhesin (Siglec-1), CD22 (Siglec-2), CD33 (Siglec-3),
myelin-associated glycoprotein (Siglec-4), Siglec-5, Sig-
lec-6, Siglec7, Siglec-8, Siglec-9, Siglec-10, mSiglec-E, MIS,
and S2V, are type 1 transmembrane proteins containing
multiple extracellular Ig-like domains that recognize differ-
ent types and linkages of sialic acid (1). Most Siglecs, in-
cluding CD22, have one or more ITIMs in their cytoplas-
mic domains, which suggests they inhibit cellular activity
(1). Each Siglec has its own unique tissue distribution, with
CD22 being the only 
 
 
 
2, 6 sialic acid binding member that
is expressed exclusively on B lymphocytes (1).
CD22 is a well-characterized negative regulator of B cell
antigen receptor (BCR) signaling (2). Upon BCR cross-
linking, its cytoplasmic portion is rapidly tyrosyl phosphory-
lated and recruits the Src homology 2 domain–contain-
ing protein tyrosine phosphatase (SHP)-1 (3, 4), which is
believed to mediate inhibitory signaling by CD22 (5).
Consistent with a role for CD22 in negative regulation of
BCR signaling, CD22
 
 
 
/
 
 
 
 mice exhibit an increased and
prolonged Ca
 
2
 
 
 
 response after BCR stimulation, an ex-
panded peritoneal B-1 cell population, and increased levels
of autoantibodies (6–9).
Although the role of the CD22 cytoplasmic domain is
fairly clear, the function of its highly conserved extracellu-
lar domain is poorly understood. Previous work established
that the most NH
 
2
 
-terminal Ig domains, Ig1 and Ig2, me-
diate 
 
 
 
2, 6 sialic acid–binding activity (10). Mutagenesis
was used to identify residues within the Ig domains essen-
tial for binding (10, 11). However, the physiological
ligand(s) for CD22 remain unknown. IgM and CD45 have
been proposed to be major CD22 ligands, but the physio-
logical relevance of these interactions has remained contro-
versial and other molecules also may bind (10, 12–14).
Interestingly, in resting B cells CD22 is bound to an en-
dogenous ligand(s) and is unavailable for binding to exog-
enous molecules (15). This “masking” of CD22 can be
relieved by treatment with sialidase or a combination of
anti-IgM and anti-CD40 (15). The significance of CD22
binding to its endogenous ligands for B cell function re-
mains unknown. Thus, it was of interest to explore the re-
lationship between the binding of CD22 to its endogenous
ligand(s) and its negative regulatory function in B cells. To
address this issue, we generated two CD22 mutants that
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lack sialic acid binding activity and introduced them into
J2–44, a novel immortalized B cell line derived from a
CD22
 
 
 
/
 
 
 
 mouse.
 
Materials and Methods
 
Cell Line and Culture.
 
The CD22
 
 
 
/
 
 
 
 J2–44 mouse cell line
was generated by immortalizing splenic B cells from (B6 
 
 
 
129)F
 
2
 
 CD22
 
 
 
/
 
 
 
 mice (6) with the J2 virus (16). Details of the
generation and characterization of these cells will be published
elsewhere. Cells were cultured in RPMI 1640 (Life Technolo-
gies) supplemented with 20% heat-inactivated FCS, 20 mM
Hepes, pH 7.4, 1 mM sodium pyruvate, 1 mM nonessential
amino acids (GIBCO BRL), 50 
 
 
 
M 2-mercaptoethanol, 100 U/ml
penicillin, and 100 
 
 
 
g/ml streptomycin sulfate.
 
Flow Cytometry.
 
Immunostaining was performed as described
previously (15). Antibodies used included biotinylated anti-B220/
CD45R antibody (BD PharMingen), biotinylated-B7.6 anti-IgM,
and biotinylated-NIM-R6 anti-CD22 mAb. Biotinylated-Sambu-
cus Nigra Agglutinin was obtained from Vector Laboratories.
Flow cytometric data were obtained and analyzed using a FACS-
Calibur™ and WinMDI software.
 
Retrovirus Generation and B Cell Infections.
 
Previously modi-
fied murine CD22.2 cDNA (17) was cloned into the NotI and
EcoRI sites of the modified MSCV 2.2 vector, which expresses
inserted genes under the control of the MCSV long terminal re-
peats and GFP by means of an internal ribosome entry sequence
(18). Mutations in CD22 were introduced in this MSCV CD22.2
construct by overlap-extension PCR (19). The two common
primers used were the forward primer MSCV-forward:
5
 
 
 
CCTACATCGTGACCTGGGAAG3
 
 
 
 
 
and the reverse primer
5
 
 
 
CD22-R2: 5
 
 
 
 GCCACGGTCCTGAGTTTCG 3
 
 
 
. The prim-
ers used to generate the DEL mutant were the reverse primer
Ig12DR: 5
 
 
 
CTTGATCTCGAGCTTCGGGGTGTACCGAG-
CCGAAGCCAC 3
 
 
 
 
 
and the forward primer Ig12DF: 5
 
 
 
ACCCCGAAGCTCGAGATCAAGGTC3
 
 
 
. The primers used
to generate the P2 mutant were reverse primer: MCD22R 5
 
 
 
TTCAGTCCCTGCGTCATCGCCAACCCCAGATTCCC 3
 
 
 
and the forward primer MCD22F: 5
 
 
 
ATGACCGCAGGGAC-
TGAAGAATGGATGGAGCCCATTCA3
 
 
 
 (mutations under-
lined). The product of the PCR reactions was digested with
EcoRI and HpaI. The digested fragment was used to replace the
WT sequence. DNA sequencing confirmed that only the desired
mutations were present.
Retroviruses were generated by transfection of 293T cells with
plasmid DNA (10 
 
 
 
g) as described previously (20, 21). Retrovi-
rus-containing 293T cell supernatants were collected 48 h after
transfection and used to infect J2–44 cells. The retrovirus-
infected cell (GFP
 
 
 
) populations were purified by FACS
 
® 
 
and
cultured as described above. Sorted, GFP
 
 
 
, cell populations were
used within a few weeks after their generation. This approach
avoided clonal variation and generated lines that expressed CD22
and mIgM for several months. Each experiment was repeated on
three to five independently infected cell populations.
 
Measurement of Ca
 
2
 
 
 
 Mobilization.
 
Ca
 
2
 
 
 
 experiments were
conducted as described previously (17). Briefly, cells were loaded
with 2 
 
 
 
M Fura-2AM/0.01% Pluronic 127 (Molecular Probes)
for 35 min at 37
 
 
 
C in Fura-2 buffer (135 mM NaCl, 1 mM
CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 10 mM glucose, 10 mM Hepes, pH 7.4,
and 0.1% high purity BSA; Roche Laboratories), washed, and
warmed at 37
 
 
 
C for 10 min before analysis. Assays were per-
formed using a SC-500 spectrofluorometer (Photon Technolo-
 
gies). Cells were activated with 1 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 anti-IgM (Jack-
son ImmunoResearch Laboratories). The emission values at 510
nm after excitation at 340 and 380 nm were collected and ana-
lyzed using FELIX software (Photon Technologies). Data was
analyzed and graphs generated with Deltagraph 4.0 software
(SPSS).
 
Immunoprecipitation and Immunoblotting.
 
Immunoprecipita-
tions were performed as described previously (17). CD22 was im-
munoprecipitated with rabbit antibody raised against the 17
COOH-terminal amino acids of murine CD22 (details to be pub-
lished elsewhere). SHP-1 was immunoprecipitated with rabbit
anti–mouse SHP-1 antibody (C-19) (Santa Cruz Biotechnology,
Inc.). Immunoprecipitates were collected on protein G Sepharose
beads (Amersham Pharmacia Biotech), which were then washed
three times in lysis buffer (1% Nonidet P-40, 150 mM sodium
chloride, 5 mM sodium fluoride, 2 mM sodium o-vanadate, 25
mM Hepes, pH 7.4, and 1 
 
 
 
g/ml leupeptin, 1 
 
 
 
g/ml aprotinin, 1
 
 
 
g/ml pepstatin, 1 
 
 
 
g/ml antipain, and 10 
 
 
 
g/ml PMSF), boiled
in Laemmli buffer, and resolved by a 10% SDS-PAGE.
Phosphotyrosine was detected on immunoblots with mAb
4G10 (1 
 
 
 
g/ml) (UBI) while CD22 and SHP-1 were detected
with anti-CD22 COOH-terminal peptide Ab (1 
 
 
 
g/ml) or anti–
mouse SHP-1 (1 
 
 
 
g/ml) (C-19; Santa Cruz Biotechnology,
Inc.), respectively, followed by the appropriate HRP-goat anti-
IgG antibody (Chemicon). Immunoblots were developed using
an enhanced chemiluminescence (ECL) kit (NEN Life Science
Products) and exposed to BioMax 
 
M
 
R film (Kodak).
 
Results
 
Expression of Wild-Type and Mutant CD22 in CD22
 
 
 
/
 
 
 
Cells.
 
To explore the function of wild-type (WT) CD22
and CD22 extracellular domain mutants, we made use of a
novel J2 virus-immortalized B cell line, J2–44, generated
from CD22
 
 
 
/
 
 
 
 mice. This cell retains high levels of mem-
brane IgM and CD45(B220), expresses surface 
 
 
 
2, 6 sialic
acids (Fig. 1 A) and responds to BCR cross-linking. A full
description of this line and its properties will be published
elsewhere.
We expressed WT or extracellular domain mutant
CD22 by using the dual expression retrovirus MSCV-
IRES-GFP, which coexpresses the gene of interest and
GFP (see Materials and Methods). As a control, J2–44 cells
were infected with the parental GFP-containing MSCV
vector. Two different ectodomain mutants of CD22 were
tested. The DEL mutant is an internal deletion that fuses
the first twenty NH
 
2
 
-terminal amino acids of CD22 to
amino acid 256; this mutant lacks Ig domains 1 and 2 (Fig.
1 B), which are necessary for CD22 sialic acid binding ac-
tivity (10). CD22 P2 has two point mutations, R130A and
R137E, in Ig domain 1 (Fig. 1 B). These point mutations
individually prevent CD22 from binding to CD45 (11).
Infected cells (GFP
 
 
 
) were purified by MoFlo and tested
for surface CD22 and IgM expression by flow cytometry
using the rat anti–mouse CD22 mAb NIM-R6, which rec-
ognizes both the DEL and P2 forms of CD22 (10) The
four infected cell pools had similar levels of surface IgM,
and the DEL, P2 and WT CD22
 
 
 
/
 
 
 
 infected cell popula-
tions expressed similar levels of surface CD22 (Fig. 1 C). 
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Increased Ca
 
2
 
 
 
 Flux in DEL and P2 CD22 Cells.
 
Previ-
ous studies have shown that loss of CD22 expression on B
cells causes increased Ca
 
2
 
 
 
 mobilization after BCR cross-
linking (6–9). We were interested in whether mutation of the
sialic acid binding domains of CD22 alters Ca
 
2
 
 
 
 mobilization.
J2–44 cells infected with WT CD22, the DEL or P2
mutants, or vector alone were stimulated with F(ab
 
 
 
)
 
2
 
 goat
anti–mouse 
 
 
 
 and Ca
 
2
 
 
 
 transients recorded. Previous stud-
ies showed that differences in Ca
 
2
 
 
 
 responses of WT CD22
and CD22-deficient mice were more obvious when a low
dose of anti-IgM was used (8). We had similar observations
with CD22-deficient variants of a transformed cell line
(WEHI 231) (17). We titrated the anti-IgM dose response
in our J2–44 cells. When we used a high dose anti-IgM (16
 
 
 
g/ml) to activate, we were unable to see any Ca
 
2
 
 
 
 re-
sponse difference between WT CD22 and CD22-deficient
cells (data not shown). In contrast, differences in Ca
 
2
 
 
 
 re-
sponses were obvious when we activated cells with a low
dose of anti-IgM, such as 1 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 of goat anti–
mouse IgM. Thus, we decided to use 1 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 anti-
IgM for experiments with CD22 variants.
As expected, vector-infected J2–44 cells, which do not
express CD22, had a significant Ca
 
2
 
 
 
 response to BCR
cross-linking. However, restoring WT CD22 expression
dramatically reduced the BCR-evoked calcium response
(Fig. 2 A). These data support previous work that indicates
that CD22 is a cell autonomous negative regulator of the
BCR calcium response (17). Interestingly, neither the DEL
nor the P2 mutants of CD22 were as effective as WT
CD22 in diminishing the calcium response (Fig. 2 A). This
indicated that to fully repress BCR activation, CD22 needs
its sialic acid binding domains. Neither mutant totally re-
stored CD22 inhibitory function.
Ca
 
2
 
 
 
 transients in response to BCR activation consist of
both release from intracellular stores and the subsequent in-
flux of extracellular Ca
 
2
 
 
 
 from the medium. We asked
whether the mutations in CD22 affected calcium release
from internal stores. Infected cells were subjected to BCR
cross-linking in the presence of EGTA (Fig. 2 B). Cells ex-
pressing CD22 DEL or P2 exhibited increased intracellular
Ca
 
2
 
 
 
 release compared with cells expressing WT CD22.
Thus, mutations in the CD22 sialic acid binding domains
diminished the ability of CD22 to inhibit Ca
 
2
 
 
 
 release from
internal stores.
 
CD22 Tyrosyl Phosphorylation and SHP-1 Association Re-
quire the CD22 Ectodomain.
 
CD22 has six cytoplasmic ty-
rosines, three of which (Y783, Y843, and Y863) are within
ITIMs. Upon BCR cross-linking, some, if not all of these
tyrosines are rapidly phosphorylated and recruit SHP-1 (3,
4), which is believed to mediate negative signaling. To
explore the mechanisms of ectodomain involvement in
CD22 function, we assessed the tyrosyl phosphorylation
status of the WT and mutant proteins. Anti-phosphoty-
rosine immunoblots of CD22 immunoprecipitates showed
Figure 1. Generation of B cell
lines expressing WTCD22 or CD22
ectodomain mutants. (A) Surface
phenotype of parental J2–44 cells.
Cells were stained with Sambuca ni-
gra lectin or the indicated Abs (filled
curve) and isotype control antibody
(unfilled curve). One of three similar
experimental results. Note that J2–44
cells are IgM , CD45(B220) ,  2, 6
sialic acid-positive and CD22-nega-
tive. (B) Structure of the CD22 mu-
tants used in this study. The first 20
amino acids are the signal peptide.
Extracellular domains are assigned as
described previously (reference 11).
Hpa I lies within the third Ig domain
and is used to clone the PCR prod-
uct. TM, transmembrane domain.
(C) Cells infected with WT and mutant CD22 containing retroviruses have similar surface IgM and CD22 expression. Cells were infected with the indi-
cated retrovirus and stained with the indicated Abs (filled curve) or isotype control antibodies (unfilled curve). Median fluorescence intensity (MFI) of
each stain is shown. DEL, del mutant-infected cells; P2, P2 mutant-infected cells; Vector, vector-infected J2–44 cells; WT, WT CD22-infected cells.
Similar staining was observed in three independently infected cell lines. 
1202
 
CD22/Sialic Acid Binding Regulates B Cell Activation
 
diminished tyrosine phosphorylation on the DEL and P2
mutant forms of CD22 after BCR cross-linking (Fig. 3 A
and C). In contrast to wild-type, there was no detectable
tyrosyl phosphorylation on the DEL and little on the P2
mutant 30 s after BCR cross-linking. However, after 1 min
(P2 mutant) or 3 min (DEL mutant), tyrosyl phosphoryla-
tion was readily detected, but was never at levels seen in
WT CD22. This is consistent with the decrease in inhibi-
tion of Ca
 
2
 
 
 
 transients seen in cells expressing these mu-
tants. Two isoforms were seen in the CD22 immunoblots.
They can be immunoprecipitated by any of three different
anti–mouse CD22 antibodies, NIM-R6, CY34, and our
own anti-COOH terminal peptide (data not shown). Two
isoforms have been observed previously and the suggestion
made that they represent different posttranslational modifi-
cations (22). A cytoplasmic isoform has been found in
transformed B cells (23). We have not addressed this issue.
To assess CD22/SHP-1 complex formation, SHP-1 was
immunoprecipitated from cells, resolved by SDS-PAGE
and immunoblotted with anti-CD22 Ab. Consistent with
the decreased tyrosyl phosphorylation of the CD22
ectodomain mutants, there was indeed less CD22 associ-
ated with SHP-1 in DEL and P2 mutant expressing cells
(Fig. 3 B and C). Again, the SHP-1 association increased
 
with the time after BCR cross-linking and the P2 mutant
had more associated SHP-1 than the DEL mutant.
 
Discussion
 
Here we have demonstrated that deletion of a sialic acid
binding domain or introduction of two point mutations,
(R130A and R137E), diminishes the negative regulatory
function of CD22. This means that the ectodomains of
CD22 are required for full function.
We favor the hypothesis that this loss of function is di-
rectly due to the loss of binding to a sialic acid containing
ligand. The R130 residue is highly conserved within the
Siglec family of sialic acid binding proteins. Previously, it
was shown that either the R130A or R137E substitution
decreased CD22 binding to the  2, 6 sialic acid of CD45 to
 5% of wild-type (11). Therefore, when both mutations are
present, ligand binding should be disrupted. As pointed out
previously, the R130A and R137E mutations are unlikely to
disrupt the overall structure of CD22 (10, 11). Indeed, we
found that the P2 mutant can still bind two CD22 mAbs,
CY34 (which binds to the Ig-like 1 and 2 ectodomains) and
NIM-R6. The DEL mutant, which contains a deletion of
the Ig-like domains, can still be recognized by mAb NIM-
R6, which suggests that the remaining five Ig-like domains
retain their native conformation. However, we cannot rule
out that these mutations result in altered protein–protein
binding mediated by unknown mechanisms.
As B cells are the only cells present in our system, it is
apparent that they must express the relevant ligands. While
the physiological ligand(s) for CD22 have not been estab-
lished, CD45 and IgM were proposed to be major endoge-
nous ligands (10, 12–14). CD45 is the predominant sialy-
lated glycoprotein on lymphocytes (24). CD22 can bind
CD45 in vitro (11, 12); however, it also binds cells lacking
CD45, which indicates that CD45 cannot be the sole
ligand (10, 12).
IgM is a proposed physiological ligand for CD22 (10,
12–14). Previously, it was found that a small percentage
( 2%) of membrane IgM is associated with CD22 (13).
Recently, quantitative confocal microscopy was used to
assess the location of CD22 in relation to IgM. CD22 was
found to constitutively associate with the BCR complex
even after mIgM ligation by soluble ligand (25). This sug-
gests a model in which ligation of mIg induces phosphor-
ylation of CD22, which can then recruit and activate
SHP-1, thereby inhibiting signaling. Therefore, the se-
questration of CD22 away from mIgM relieves its ability
to function as a negative inhibitor (3). Perhaps, in our
case, mutation of the CD22 ligand-binding domain pre-
vented binding of IgM. As a result, when activated, CD22
may not be in a location critical for phosphorylation of its
tyrosines.
Previous studies suggested that individual Ig-like do-
mains of mouse CD22 might be responsible for interacting
with different glycoproteins (10). Soluble recombinant
proteins containing different murine CD22 Ig-like domains
immunoprecipitated different glycoproteins from B cell
Figure 2. DEL and P2 mutant cells have increased Ca2  transients.
Shown are representative real time Fura-2 ratios (340:380) for cells acti-
vated with 1  g/ml F(ab )2 anti-IgM. (A) Cells expressing the indicated
CD22 construct or vector alone were activated by BCR cross-linking and
total calcium flux was monitored. (B) Ca2  release was measured by acti-
vating cells in the presence of 2 mM EGTA. Representative of three or
more experiments with independently infected cells.1203 Jin et al. Brief Definitive Report
lines (10). Therefore, it is possible that the DEL mutation
disrupted CD22 binding to more ligands than did the P2
mutations. As a result, the negative regulatory function of
CD22 might be more diminished by the DEL mutation.
SHP-1 is the major negative effector known to associate
with CD22 after BCR cross-linking. However, SHIP also
associates with CD22, regulating calcium transients (22).
Since the mutants phosphorylated poorly, it is possible that
their association with other negative effectors, including
SHIP, is also affected.
It appears that CD22 binding to endogenous  2, 6 sialic
acid–containing ligands contributes to the inhibition of B
cell signaling. Relief of this binding in vivo may lower the
threshold for B cell activation. While most resting splenic
and mesenteric lymph node B cells showed masked CD22,
2–5% of IgD  murine B cells had unmasked CD22 (15,
26). It is possible that within specific lymphoid microenvi-
ronments the threshold for activation for some B cells will
be lower. One possibility is that CD22 binding to ligands
on adjacent cells (trans binding) might relieve negative reg-
ulation that requires self (cis) binding. Moreover, it was
shown that a combination of IgM and CD40 mediated-
activation, as might be expected to occur in the secondary
lymphoid organs, could unmask CD22 (15). Therefore, in
the secondary lymphoid organs, previously activated B cells
might be relieved of CD22 suppression and be more sensi-
tive to stimulation by antigen.
The question remains how the disruption of CD22
binding to endogenous ligands alters its inhibitory affect on
BCR signaling. The observed decrease in tyrosine phos-
phorylation of mutant CD22 is likely to be key, as SHP-1
association and negative regulation of Ca2  are believed to
be downstream of CD22 phosphorylation. Yet to be ex-
plained is how CD22 phosphorylation can be affected by
the disruption of binding to endogenous ligand(s). One
possibility is that the disruption of CD22–sialic acid bind-
ing domains alters the placement of CD22 within the cell
so that the critical kinase is less able to access CD22. An-
other possibility is that the activity of the kinase responsible
for CD22 phosphorylation is altered by the disruption of
CD22 ligand-binding domains. Lyn is a likely candidate. It
can phosphorylate CD22 cytoplasmic peptides in vitro
(22), and its loss in Lyn /  mice causes decreased phosphor-
ylation of CD22 (27, 28). Furthermore, phosphorylation
of murine CD22 ectopically expressed in the transformed
chicken B cell line DT40 is Syk and Lyn dependent (29).
Interestingly CD45, a putative CD22 ligand on B cells, is a
regulator of Lyn (30, 31). Lyn has two critical tyrosines: a
stimulatory autophosphorylation site and an inhibitory
COOH-terminal phosphorylation site. While CD45’s role
in negative or positive regulation of Lyn is still under dis-
cussion (30, 31), CD45 can dephosphorylate either tyro-
sine. Thus, it is possible that the disruption of CD22 bind-
ing to its ligand(s), perhaps including CD45 itself,
somehow affects CD45’s ability to dephosphorylate the
critical tyrosines of Lyn. As a result, the kinase activity of
Lyn would be affected, thereby altering phosphorylation of
CD22. However, we have not detected altered phosphory-
lation of Lyn at either site after activation of cells expressing
mutant CD22 (unpublished data).
B cells from CD22-deficient mice have decreased cell
proliferation and increased apoptosis upon anti-IgM cross-
Figure 3. Decreased CD22 tyrosyl phosphorylation and
SHP-1 association in CD22 ectodomain mutants (n   3).
(A) J2–44 cells expressing WT or mutant CD22 or vector
alone were assayed in the absence of stimulation or at the
indicated times after BCR cross-linking. CD22 was immu-
noprecipitated with rabbit anti–mouse CD22 COOH-ter-
minal peptide. Cells were assayed at different times after
activation. The blot was first probed with 4G10 mouse
anti-phosphotyrosine Ab, stripped and reprobed with anti-
CD22 COOH-terminal peptide Ab. (B) SHP-1 was immu-
noprecipitated with rabbit anti–mouse SHP-1 Ab. Cells
were assayed at different times after activation. The blot
was first probed with anti SHP-1 Ab, stripped, and re-
probed with anti–CD22 COOH-terminal peptide. (C)
Quantitative analysis of the results shown in a and b. The
intensities of the bands were quantified by densitometry. The intensities of the P-tyr and CD22 bands were normalized by reference to a loading control.
The densities of bands in the WT lysates at 3 min was set as 100%. The percentage of activation was calculated by comparing the corrected intensity of
the bands with the 100% control (the activation of WT at 3 min). Mean results from five experiments are shown ( SD), P   0.05 by Student’s t test.1204 CD22/Sialic Acid Binding Regulates B Cell Activation
linking (6–9). As yet, we have not generated convincing
data to show that cell proliferation and apoptosis of these
transformed cells is altered after F(ab )2 activation (data
not shown).
Our results indicate there is a connection between two
crucial events regarding CD22: the phosphorylation of
CD22 and the ligand binding of its ectodomains. Future
work will be directed at understanding the mechanisms by
which binding of CD22 to endogenous ligand(s) affects its
phosphorylation status. Like CD22, many Siglecs have Ig-
like binding ectodomains and ITIM motifs in their cytoplas-
mic tails. They recognize different types and linkages of sialic
acid and have different tissue distributions. Therefore, our
finding that the sialic acid binding domains of CD22 are re-
quired for negative regulation may have broad implications.
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